New trials, publications, preprints and grants on this target, month by month.
Trial
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
9 Apr 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
31 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
15 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
11 Nov 2026· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publication
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.
3 Nov 2026· Blood cancer discovery· PUBMED
Publication
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2 Nov 2026· Cancer discovery· PUBMED
Publication
Expanding the RAS-verse: Novel Inhibitors, Emergent Dependencies, Fresh Opportunities in RAS-Mutant NSCLC.
2 Nov 2026· Cancer discovery· PUBMED
Publication
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers.
2 Nov 2026· Cancer discovery· PUBMED
Trial
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC.
1 Nov 2026· Nature reviews. Clinical oncology· PUBMED
Publication
Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.
1 Nov 2026· British journal of cancer· PUBMED
Trial
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
29 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
ACK1 inhibition suppresses topoisomerase IIα, causing DNA damage accumulation and cellular senescence in RAS mutant lung cancer cells.
28 Oct 2026· Oncogene· PUBMED
Publication
Re: "Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer.".
24 Oct 2026· Asia-Pacific journal of clinical oncology· PUBMED
Publication
Response Letter: Re: "Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer".
22 Oct 2026· Asia-Pacific journal of clinical oncology· PUBMED
Publication
Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.
22 Oct 2026· Experimental hematology & oncology· PUBMED
Publication
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.
16 Oct 2026· Blood· PUBMED
Publication
Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses.
16 Oct 2026· Oncogene· PUBMED
Publication
RAS pathway mutations orchestrate chromatin reconfiguration and transcriptional rewiring in colorectal cancer.
14 Oct 2026· Cell communication and signaling : CCS· PUBMED
Publication
[Analysis of efficacy and prognostic factors of neoadjuvant chemoradiotherapy in locally advanced mid-low rectal cancer patients with RAS gene mutation].
13 Oct 2026· Zhonghua yi xue za zhi· PUBMED
Publication
Blockade of mutant RAS oncogenic signaling: A 2026 update.
11 Oct 2026· Pharmacological research· PUBMED
Publication
RAS-Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer.
1 Oct 2026· Cancer medicine· PUBMED
Publication
[Two Cases of Multiple Colorectal Cancer in Which Circulating RAS Mutation Analysis by BEAMing Was Useful for Identifying the Recurrent Primary Lesion].
1 Oct 2026· Gan to kagaku ryoho. Cancer & chemotherapy· PUBMED
Publication
Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.
30 Sept 2026· Blood cancer discovery· PUBMED
Publication
Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.
28 Sept 2026· Experimental hematology & oncology· PUBMED
Publication
Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review.
25 Sept 2026· Cancers· PUBMED
Preprint
Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.
18 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification.
16 Sept 2026· Cureus· PUBMED